Malignant neoplasm of gastrointestinal tract – Talk Bio

Actionable Insights Powered by AI

Marengo’s invikafusp alfa shows promising monotherapy activity in PD-1 resistant gastrointestinal cancers

2 weeks ago talkbio0Tagged Alfa, Colorectal Carcinoma, fast-track designation, High tumor mutational burden, High-Frequency Microsatellite Instability, Immunotherapy, invikafusp, Malignant neoplasm of gastrointestinal tract, Marengo Therapeutics, PDCD1 gene, resistant tumors, United States Food and Drug Administration

Invikafusp alfa; Marengo Therapeutics; PD-1 resistant tumors; Gastrointestinal cancers; Colorectal cancer; TMB-H; MSI-H; Immunotherapy; ESMO 2025; FDA Fast Track designation

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

11 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement